688062 迈威生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-85.317-101.057-50.278-34.542-42.206
总资产报酬率 ROA (%)-10.592-21.952-23.914-23.217-30.741
投入资产回报率 ROIC (%)-12.205-25.285-27.048-25.631-33.308

边际利润分析
销售毛利率 (%)75.46290.27085.50898.92899.745
营业利润率 (%)-165.323-144.196-522.310-823.385-3,455.471
息税前利润/营业总收入 (%)-145.478-131.216-505.925-851.640-3,580.798
净利润/营业总收入 (%)-167.669-146.752-523.854-828.261-3,455.423

收益指标分析
经营活动净收益/利润总额(%)97.725101.622101.19899.315100.790
价值变动净收益/利润总额(%)0.9530.8870.3560.445-0.187
营业外收支净额/利润总额(%)1.3260.1130.3810.257-0.001

偿债能力分析
流动比率 (X)1.2490.9031.1062.5086.241
速动比率 (X)1.1630.8190.9692.3136.063
资产负债率 (%)80.08588.30163.61242.24024.004
带息债务/全部投入资本 (%)73.30979.88554.50629.07314.780
股东权益/带息债务 (%)25.31011.38975.237228.261549.751
股东权益/负债合计 (%)20.5998.68857.685137.299317.053
利息保障倍数 (X)-6.593-9.985-27.52232.58528.561

营运能力分析
应收账款周转天数 (天)65.44737.52950.32324.7611.398
存货周转天数 (天)452.3751,115.7312,306.48831,319.667303,610.354